Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
shortie getting nervous, knocked pps down at 2:59.
closer every day to azz kicking.
I DK how accurate this is, but get happy every time I contemplate a classic squeeze:
Number of Floating Shares 32.3 M
Short Interest as % of Float 2.74%
a surprise earning report will be the catalyst
ides of march-----------
WOW, update: got hit on all my bids. accumulated equivalent of 12,600 shares.
Bidding for more.
LOL WOW, we are thinking the same exact thing re future pps.
I grabbed options = to 4100 shares all the way to June & Sept.
ARGUING with myself about grabbing equivalent to 10K shares.
Might wait till manana.
right now there are 20k shares available @ 3.25 till JUNE 21
for $ 15k. buying 20 k shares @ 2.96 (current pps) would cost $ 59,200.
Couldn't help myself. Had to gather a few more. Wth
"Company’s rapidly growing EFT services”
"as we scale our processing operations to accommodate our transaction volume growth,”
WOW, This is getting SERIOUS.
i want 4.00+
This is an older article from Logan. It seems transparency is very lacking in patient affordability and a ton of money slips through the cracks. Paysign has "cracked the code".
https://www.drugchannels.net/2022/06/exposing-facts-about-voucher-and-bridge.html?m=1
Busy as bees
Source: Business Wire
Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, today announced their first-time sponsorship of the 7th Annual Gene Therapy for Rare Disorders conference to be held March 26-29, 2024, in Boston, Massachusetts.
In keeping with their commitment to patient affordability and access, Paysign is sponsoring the annual event as an Exhibition Partner. The conference is the gene therapy industry’s leading event where key figures, service providers, payers and regulators discuss insights to the crucial challenges that face these programs today.
"We are thrilled to add this event to our annual schedule of sponsorships and to provide much-needed representation for patient affordability solutions that tackle the biggest issues facing access to gene therapy for rare disorders,” said Matthew Turner, President, Patient Affordability at Paysign.
Stop by and see the Paysign team at their booth to network and gain fundamental insights on how to mitigate barriers to patient access. To learn more about Paysign’s patient affordability solutions, visit paysign.com/rx.
Visit the Gene Therapy for Rare Disorders conference website to learn more and register for the event.
I believe we'll get a clearer vision on the pharma trajectory in exactly two weeks. My optimism is spiked
i figured it still favors the concept---REMEMBER OLD FRIEND: Covid was a psychological negative for such things altogether.------This helps our cause.---------------------------------------------I admit, t'is my pump. lol
Mr D, SELLING, not 'GIVING"
a week ago i happened upon some laura ingram show and she was pumping how more citizens are blood/plasma giving----------and just a minute ago here comes famous peyton manning brand new commercial sponsoring giving of blood similarly-----------on nfl channel-----------food for thought--------------gas is rising again, too....as is all inflation, too....--------------------------------------------------------------------------------could there be a good qtr coming? Methinks so.
WOW, , ,
need to keep accumulating
But wait, there's more.
https://drugch.nl/3TsMJlF
I hope this webinar shows below. Quite informative. I'll need to watch again with Google helping me with the lingo
https://app.gotowebinar.com/unified/index.html#/webinar/5032756528412644959/attend/726543427794374747
Pharma Karma
Source: Business Wire
Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, today announced their sponsorship of the 2024 ACCESS USA Conference to be held March 19-21, 2024, in Philadelphia, PA.
Paysign has been a long-time supporting sponsor of the Informa Connect series of life sciences events that focus on topics such as patient affordability, access and hub and specialty networks, issues the company is committed to addressing with its suite of solutions for the pharmaceutical industry.
ACCESS USA combines three events: Patient Assistance and Access Programs, Hub and Specialty Pharmacy Models and Rare Disease Summit. The conference agendas are set to take on critical conversations including the state of the industry, regulatory reform and ethical considerations by top leaders across the life sciences industry.
“We’re excited to support one of our industry’s leading conferences, where we can contribute to the exchange of ideas shaping the future of patient access and better help our clients navigate the ever-changing patient policy and financial landscape,” said Matthew Turner, President, Patient Affordability at Paysign.
Visit Matthew Turner and Paysign’s team of patient affordability experts at booth #415 to learn more about their innovative solutions or visit paysign.com/rx.
To learn more about the ACCESS USA conference, visit the event website.
March options expire Friday. Expect some manipulation.
Considering the $5M share buy-back, the 6 million Topline shares, and the many deep-pocket longs, the float has to be getting mighty thin
Topline Capital busy this week. Nearing 6 Million shares!
https://www.secform4.com/filings/1496443/0001754074-24-000006.htm
I believe many will have something to say after Q
I'll drop him a note. Think after Q he will certainly have something to say.
Time for E to stop by and give us his thoughts.
Your are spot on about the shortie gang. Nice job on the calls!
special thanks to the shortie gang for contriving the selloff. This happy camper loaded the boat with sept 2.50 calls and march 2.50 calls. '24 is going to make the few of us here fat & sassy.
wonder if janey is still aboard?
god bless ya chilar for carrying the flag here------great board.
CORNER TURNED:
Performance 3 Month 1 Year
Performance of S&P 500 11.73% 28.87%
Performance of PAYS 20.58% -25.26%
Performance of Industry Index -4.21% -16.67%
Number of Floating Shares 32.3 M
Short Interest as % of Float 2.75%
got some @ 2.76
still a big #
Number of Floating Shares 32.3 M
Short Interest as % of Float 2.75%
Added a few more shares this morning. cheap in my view.
yep, they're frisky as heck today. it always seems to happen as option expiration approaches. today I LOADED june & sep 2.50 calls. paid some premium but the sellers have to hold the shares.
Good opportunity presently as shorts are having their way recently.
i'm loading the boat with june & sep 2.50 calls.
very small premiums but huge leverage and effective allocation of powder.
Nice grab jpike!
I just added at 2.88.
I just added at 2.88.
X2!
Remember: Mark said the patient affordability market "dwarfs" plasma and they're pulling business from companies with decades of experience with the largest pharmaceuticals in the world.
Let the Snowball affect commence!
Deep pockets
Pharma Karma
WOW, great info. I think eventually
Patient affordable will eclips plasma.
This may explain why they pushed fins back a week. They're a bit busy with patient affordability.....
Paysign is excited to be a sponsor at the Informa Connect ACCESS USA conference held in Philadelphia, PA, on March 19-21, 2024 - where vital and thought-provoking discussions about the future of patient access will take place. http://bit.ly/431OSYK
#events #AccessUSA #patientaffordability
HENDERSON, Nev. – February 27, 2024 – (Business Wire) – Paysign, Inc. (NASDAQ: PAYS), a leading provider of prepaid card programs, comprehensive patient affordability offerings, digital banking services and integrated payment processing, will discuss fourth quarter and full year 2023 earnings at 5:00 p.m. EDT on Tuesday, March 26, 2024.
52 week high 3.99>>>looks like where we're headed---glta
Topline Capital added another 77k shares, bringing total holdings to 5.76 million. They just cannot get enough!
https://www.streetinsider.com/dr/news.php?id=22812520&gfv=1
Followers
|
54
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
9489
|
Created
|
07/02/10
|
Type
|
Free
|
Moderators chilar4567 |
- Revenue for the year ending December 31, 2018 was $23.4 million, an increase of 54% compared to $15.2 million the prior year.
- Gross profit increased 70% to $11.4 million or 49% of revenues, compared to $6.7 million or 44% of revenues in 2017.period last year.
- Non-GAAP Adjusted EBITDA was $4.9 million, an increase of 65% compared to $3.0 million in 2017. Non-GAAP Fully Diluted EPS was $.09 as compared to $.06 the prior year.
- The company reiterates its previously released revenue guidance for 2019 of $38.0 to $40.0 million, representing a 62% to 71% increase compared to $23.4 million for full year 2018
as well as an adjusted EBITDA guidance at $10.0 to $12.0 million, representing a 104% to 145% increase compared to $4.9 million for full year 2018.
The PaySign platform represents a revolutionary payment processing solution that took years of development. It is a reflection of the Company's commitement to providing innovative, cost effective, customizable payment solutions to a variety of industries for multiple purposes. The platform was designed to easily incorporate new payment technologies and applications as they evolve, keeping Paysign at the forefront of payment innovation.
--> Corporate Incentives: In a market that is expected to grow to $26.5 billion by 2016, PaySign® corporate incentive cards are the perfect vehicle for
corporations looking to engage and motivate their customers, employees, and trade partners. PaySign cards are perfect for customer rebates, employee
bonuses and trade partner commissions. Examples of corporate incentive cards include prepaid cards used as incentives to purchase big ticket items such
as automobiles, smartphones and major appliances.
--> Payroll: PaySign payroll cards reduce administration costs and streamline operations for companies looking to provide an efficient payment method for
unbanked employees. The overall market for prepaid debit cards for payroll is expected to reach $66.4 billion by 2016.
--> Public Sector: Federal and local governments, educational institutions, and other public sector organizations are constantly looking to improve efficiency
and reduce costs. The PaySign card for the public sector provides an effective way to reduce costs and inefficiencies, whether related to disbursements of
public benefits or internal payments. The total prepaid card market for government payments is projected to reach $119.4 billion by 2016.
--> Pharmaceutical Co-Pay Assistance: Paysign's Allegiance Rx card is now available under the PaySign brand. Co-pay assistance cards have been
utilized by major pharmaceutical companies for brands such as Viagra®, Vyvance® and Restasis® to name a few.
--> Source Plasma Donors: Plasma collection companies nationwide can turn to the PaySign brand of cards for a customized payment solution for plasma
donors. The PaySign solution offers either a customized Plasma Web portal solution or direct integration into donor management software.
- Co-founded the Company in 2001; and driving force behind the Company's significant growth and strategic direction
- Shaping the future of the business as a premier prepaid card services leader, delivering a strong value proposition for clients and over 2 million cardholders; oversees all financial, operational, technological and strategic decisions for the company, including: technology investments, the evaluation of strategic acquisitions,new product development and the formation and cultivation of third-party relationships
- Served on the X-9 committee which developed standards for the electronic payments industry alongside IBM, Diebold, First Data, KPMG, MasterCard, Melon Bank, Visa, Wells Fargo, the Federal Reserve and others
- Attended Cal-Poly San Luis Obispo where he majored in Bio-Science
- Co-founded the Company in 2001
- 30+ years of senior IT experience
- Prior experience includes Director of Technology Planning at the Associated Press, Project Manager of implementation of Medicare Easyclaim for ANZ Bank in Australia, Coca-Cola Business Operations & Business analyst for Australia Post
- 30+ years of experience in Financial Services and BPO industries with concentration in Finance, Operations and executive leadership
- Prior experience includes CEO and CFO of Zxerex, CEO of Affina, and Vice President at American Express and Vice President at NextCard
- Bachelor of Science in Finance, minor in Accounting; and Masters in Business Administration (MBA) from Brigham Young University
- 30+ years of industry experience
- Previously at Sunrise Banks as Senior Vice President, Payments Division where she led the new prepaid business
- Prior experience includes various management positions in operations, product development, and sales and marketing at UMB Bank, Heartland Bank, and Boatmen’s Bank
- Board member of the Network Branded Prepaid Card Association and serves as Treasurer
- 13+ years of legal experience in non-traditional banking
- Previously at Republic Bank & Trust Company (Louisville, KY) as Deputy General Counsel and Vice President where he managed all legal affairs for Republic’s non-traditional bank programs, including payments, small-dollar consumer lending, commercial lending and tax related products
- B.A. in Psychology and Philosophy from the University of Kentucky and J.D. from DePaul University College of Law in Chicago, Illinois
- 20 years of experience working in the card industry, focusing on prepaid and credit products
- Previously with Global Cash Card, Inc., Sunrise Banks and Meta Payment Systems (a division of Meta Bank)
- Certified member (CAMS) of the Association of Certified Anti-Money Laundering Specialists.
- Bachelor of Science Degree from South Dakota University
- 30+ years experience in various technical roles providing enterprise IT services at several global companies
- Former Associate Director, Hosting Solutions Bristol-Myers Squibb
- Former Manager of Server Technology, The Associated Press
- 25+ years experience in various marketing roles within the Fintech industry
- Former Senior Product Marketing Manager at Fiserv
- Former Vice President, Marketing, NYSE Governance Services
Board of Directors
- Former CEO of NetSpend (2008-2013). Grew annual revenue from $129M to $351M, with over 2.4 million cardholder accounts. NetSpend acquired by Total System Services: (NYSE: TSS) for $1.4B
- Co-founder, Former President and Chief Operations Officer and Director at Euronet Worldwide (NASDAQ: EEFT). A leader in secure electronic financial transaction processing. Current market cap: 5.4B
- Sits on Board of The Brinks Company. (NYSE: BCO), CARD Corporation (Card.com), RxSavings Solutions, Balance Innovations and Align Income Share Fund
- Received a B.S. in Business Administration with majors in Finance, Economics and Real Estate from the University of Missouri,Columbia
- 35+ years in the banking industry including serving as the President and CEO of two banks in the Midwest
- Former CEO of Healthcare Services at UMB Bank, N.A a leading provider of healthcare payment solutions including health savings account (HSAs), health care spending accounts and payments technology
- 30+ years of legal experience focusing on mergers and acquisitions, public and private securities offerings, and venture capital transaction
- Serves as corporate counsel for numerous public/private companies and was formerly general counsel and board member of Swensen’sInc.
- Mr. Williams is a shareholder with Greenberg Traurig LLP and admitted to the Bar in New York and Arizona
- 30+ years of experience as a Certified Public accountant
- Founder and Managing member of Mina Llano Higgins Group, LLP
- Former CFO of Coal Brick Oven Pizzeria, Inc.
- Currently CFO for Academy of Aviation in Long Island, NY
3PEA International:
Jim McCroy
Investor Relations
Tel: 702.749.7269
IR@3PEA.com
www.3pea.com
Website
Click Here For the Company's Investor Presentation
Articles About 3PEA International
Seeking Alpha (SC Capital Group) - 3Pea Is A Payment Processor With >40% Organic Growth Selling For Half Of Peer Multiples - 2018-05-22
Seeking Alpha (Inefficient Market) - 3Pea: Strong Guidance, Uplisting, Should Propel Shares Higher - 2018-04-03
Seeking Alpha (BW Investment Visibility) - 3Pea International: Undervalued And Undercovered Turnaround Story - 2017-11-20
Analyst Coverage
Cannacord Genuity: Buy 17$ Target
Ladenburg Thalmann: Buy 14.50$ Target
Maxim Group: Buy 10.00$ Target
*This document contains projections and other forward-looking statements regarding future events. Such statements are predictions, which may involve known and unknown risks, uncertainties and other factors, which could cause the actual events or results and objections to differ materially from those expressed.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |